OTC drugs-of-abuse test policy will be "re-examined" -- FDA tells Congress.
This article was originally published in The Tan Sheet
Executive Summary
FDA ADVISORY PANEL TO "RE-EXAMINE" POLICY FOR OTC DRUGS-OF-ABUSE TESTS, which are currently considered Class III medical devices, Bruce Burlington, director of the agency's Center for Devices and Radiological Health, said at a Sept. 26 House Commerce/oversight subcommittee hearing. Responding to Rep. Ron Klink (D-Penn.), Burlington said, "We, in fact, do need to re-examine" the policy.